Misoprostol 25 mcg Tablets

Misoprostol 25 mcg Tablets contain misoprostol, a synthetic prostaglandin E1 analogue that affects the uterus and cervix. Certain authorized low-dose tablet formulations are used to help initiate labour in pregnant patients when medically indicated.

Misoprostol promotes cervical ripening and uterine contractions. Its use for labour induction requires an appropriate obstetric assessment and monitoring of both the mother and baby.

The approved indication depends on the particular product and country. The 25 mcg labour-induction formulation should not be confused with other misoprostol tablet strengths or combination products.

Product Information

• Product Name: Misoprostol 25 mcg Tablets
• Active Ingredient: Misoprostol
• Strength: 25 micrograms per tablet
• Dosage Form: Oral tablet, depending on the specific product
• Drug Class: Prostaglandin E1 analogue
• Therapeutic Category: Obstetric medicine
• Use: Labour induction for authorized formulations
• Product Reference: Angusta 25 microgram tablets in markets where authorized
• Administration: Under the applicable product instructions and obstetric protocol
• Pack Size: Verify the actual product packaging
• Prescription Requirement: Subject to local regulations

Uses and Benefits

Certain authorized misoprostol 25 mcg tablet products are used for:

• Labour Induction: Helps initiate uterine contractions when induction is medically indicated.
• Cervical Ripening: Helps prepare the cervix for labour.
• Obstetric Care: Provides a pharmaceutical option for labour induction under appropriate clinical supervision.

The suitability of misoprostol depends on the pregnancy, cervical assessment, obstetric history and applicable product authorization. It is not appropriate for every patient.

Dosage and Administration

Misoprostol 25 mcg tablets must be administered according to the exact product label and the treating obstetric team’s protocol.

The dose, administration interval and maximum amount depend on the authorized product and the patient’s clinical circumstances. Do not use a general dosing schedule in place of the hospital’s obstetric protocol.

This product must not be self-administered for labour induction. Administration requires trained obstetric personnel and access to monitoring of uterine contractions and fetal wellbeing.

Do not substitute a 25 mcg product with a 200 mcg tablet or another formulation without explicit clinical direction.

Possible Side Effects

Possible adverse effects include:

• Nausea or vomiting
• Diarrhoea
• Abdominal pain
• Fever or chills
• Excessive or prolonged uterine contractions
• Changes in the baby’s heart rate associated with uterine overstimulation

Serious complications can include uterine rupture, fetal distress and other severe obstetric emergencies.

The obstetric team should assess adverse symptoms and monitor the mother and baby during treatment.

Warnings and Precautions

Before administration, the obstetric team must review pregnancy history, previous uterine surgery, fetal presentation, placental position and other relevant clinical factors.

Important precautions include:

• Uterine overstimulation: Misoprostol can produce contractions that are too frequent, prolonged or strong.
• Previous uterine surgery: Certain products are contraindicated in patients with a uterine scar, including from a previous caesarean delivery.
• Fetal wellbeing: Assessment and monitoring are necessary according to the obstetric protocol.
• Other labour-induction medicines: Combining misoprostol with oxytocin or other uterotonic agents requires strict adherence to product-specific timing and contraindications.
• Pregnancy-related risks: The suitability of induction must be assessed by an obstetric professional.

The specific contraindications vary by product. Follow the official product leaflet and local hospital protocol.

Storage Instructions

Store the tablets according to the manufacturer’s instructions and the official product leaflet. Certain misoprostol tablets require protection from moisture and storage in their original packaging.

Check the expiry date and packaging before use. Do not use products that have expired, have damaged packaging or have been stored outside the specified conditions.

Ordering and Availability

For Misoprostol 25 mcg tablet pricing, pack sizes and availability, contact the supplier to confirm the exact formulation, manufacturer, packaging and current stock.

Regulatory authorization, dispensing requirements and import eligibility vary by country. Verify that the specific product is authorized for the intended clinical use in the destination market before ordering.

Frequently Asked Questions

1. What are Misoprostol 25 mcg Tablets used for?

Certain authorized 25 mcg formulations are used for labour induction under hospital supervision.

2. Is Misoprostol 25 mg the same as Misoprostol 25 mcg?

No. One milligram equals 1,000 micrograms. A 25 mg tablet would contain 1,000 times the amount in a 25 mcg tablet. Check the actual packaging carefully.

3. What is the brand reference for Misoprostol 25 mcg tablets?

Angusta is a recognized brand of misoprostol 25 microgram tablets in certain markets. Availability and authorization vary by country.

4. Can the 25 mcg tablet be substituted for a 200 mcg tablet?

Do not substitute different strengths or formulations without direction from the treating healthcare professional. Their authorized uses and dosing protocols can differ substantially.

5. What is the price of Misoprostol 25 mcg Tablets?

Price depends on the manufacturer, pack size, supplier and destination country. Contact the supplier for a current quotation.

6. Can Misoprostol 25 mcg Tablets be used at home to induce labour?

No. Labour induction with these products requires trained obstetric personnel and appropriate hospital monitoring.

Medical Disclaimer

This description is for general product information and does not replace professional medical advice, diagnosis or treatment. Misoprostol can cause serious obstetric complications and must be used according to the approved product instructions and appropriate clinical supervision. Confirm the exact strength and formulation on the actual product label before listing or use.

Last Updated: October 25, 2026